MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma

In general, our work illustrates that it is the MAX to MYCN ratio that can account for tumour progression and clinical outcome in neuroblastoma and proposes that such a ratio should be considered as an important criterion to the design and development of anti-MYCN therapies.